GENINCODE PLC LS -01
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to prov… Read more
GENINCODE PLC LS -01 (9PL) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GENINCODE PLC LS -01 (9PL) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GENINCODE PLC LS -01 - Net Assets Trend (None–None)
This chart illustrates how GENINCODE PLC LS -01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GENINCODE PLC LS -01 (None–None)
The table below shows the annual net assets of GENINCODE PLC LS -01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GENINCODE PLC LS -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GENINCODE PLC LS -01 Competitors by Market Cap
The table below lists competitors of GENINCODE PLC LS -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LOWE'S COM - Dusseldorf Stock Exchang
DU:LWE
|
$2.01 Million |
|
PT Raja Roti Cemerlang Tbk
JK:BRRC
|
$2.01 Million |
|
Amundi Physical Gold ETC C
AS:GOLD
|
$2.01 Million |
|
Pacific Health Care Organization Inc
OTCQB:PFHO
|
$2.01 Million |
|
CBOE HLDGS
BE:C67
|
$2.00 Million |
|
Kingwell Group Ltd
PINK:SNNHF
|
$2.00 Million |
|
Everything Blockchain Inc.
PINK:EBZT
|
$2.00 Million |
|
SCUT SA BACAU
RO:SCBC
|
$2.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENINCODE PLC LS -01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GENINCODE PLC LS -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GENINCODE PLC LS -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GENINCODE PLC LS -01's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENINCODE PLC LS -01 (9PL) | €- | N/A | N/A | $2.01 Million |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |